Therapeutic Plasma Exchange: A Cross-sectional Study from a Tertiary Care Centre, Srinagar, India
Introduction: Therapeutic Plasma Exchange (TPE) is a procedure in which blood is passed extracorporeally through an automated cell separator which separates plasma from cellular components of blood. The plasma (along with diseased component) is removed and replaced with a replacement solution colloi...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Pvt. Ltd.
2023-10-01
|
| Series: | National Journal of Laboratory Medicine |
| Subjects: | |
| Online Access: | https://www.njlm.net/articles/PDF/2756/63213_CE[Ra1]_F(IS)_PF1(PS_SHU)_redo_PFA_NC(SHU)_PN(SHU).pdf |
| Summary: | Introduction: Therapeutic Plasma Exchange (TPE) is a procedure in which blood is passed extracorporeally through an automated cell separator which separates plasma from cellular components of blood. The plasma (along with diseased component) is removed and replaced with a replacement solution colloid/crystalloid.
Aim: The aim of the study was to assess the outcome of TPE.
Materials and Methods: The present study was a hospital-based cross-sectional study conducted in the Department of Blood Transfusion and Immunohaematology at Sher-i-Kashmir Institute of Medical Science, Soura, Srinagar, Jammu and Kashmir, India, over a period of 20 months from February 2021 to September 2022. All the patients sent from various Departments for TPE had to fulfill some basic formalities like: informed consent (after explaining the procedure, risks, benefits and alternative treatment options) and some baseline investigations {Complete Blood Count (CBC), Liver Function Test (LFT), Kidney Function Test (KFT), electrolytes, triple serology, coagulation profile, serum protein, blood grouping etc.,}. The rationale was that the substance to be removed should exist in plasma that contributes to a symptom/disease, large enough (>15000 D) that it can’t be removed by conventional therapy and should have prolonged half life. Data was collected in Microsoft excel and descriptive statistics was used for the analysis of data in terms of frequencies and percentages.
Results: A total of 20 patients underwent TPE. A 12 (60%) of patients were males. A 11 (55%) of patients were in the age group of 20-40 years. Good response {improvement in laboratory (lab) and clinical parameters} was found in 15 (75%) of patients while no response was shown by 5 (25%) of patients. A 3 (15%) of the patients suffered mild adverse [Two patients suffered nausea and vomiting and one patient suffered mild allergic reactions (rashes and urticaria)] reactions which were managed by antiemetic and antiallergic medications.
Conclusion: The TPE has placed blood centres and transfusion services in the position of providing direct medical care for a patient. It is a useful treatment modality (usually temporary) used in a variety of life-threatning conditions. It is not only safe and effective treatment but also cost-effective and alternative to Intravenous Immunoglobulin (IVIG). |
|---|---|
| ISSN: | 2277-8551 2455-6882 |